← Back to Clinical Trials
Recruiting NCT07330284

NCT07330284 Cold Water Irrigation Therapy as an Adjunct to Indomethacin for Post-Endoscopic Retrograde Cholangiopancreatography(ERCP) Pancreatitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07330284
Status Recruiting
Phase
Sponsor University of Kansas Medical Center
Condition Pancreatitis
Study Type INTERVENTIONAL
Enrollment 950 participants
Start Date 2025-12-05
Primary Completion 2029-07

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cold waterWarm water

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 950 participants in total. It began in 2025-12-05 with a primary completion date of 2029-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is designed to learn whether rinsing the papilla with cold water at the end of an ERCP procedure, in addition to standard medicine, can help lower the chance of developing pancreatitis, which is the most common major complication after ERCP.

Eligibility Criteria

Inclusion Criteria: * Native papilla present. * Undergoing ERCP for diagnostic or therapeutic indications. * Able to provide informed consent. Exclusion Criteria: * Post-operative reconstructed intestinal tract other than Billroth I reconstruction. * Acute pancreatitis at the time of ERCP. * Chronic pancreatitis. * Pancreatic head cancer with occlusion of the main pancreatic duct. * Existing pancreatic duct stent or need for prophylactic pancreatic duct stenting during the index ERCP. * Known contraindications or allergy to indomethacin or other NSAIDs. * Significant renal impairment (eGFR \< 30 mL/min/1.73m²). * Active peptic ulcer disease or history of NSAID-induced gastrointestinal bleeding.

Contact & Investigator

Central Contact

Reza Hejazi

✉ rhejazi@kumc.edu

📞 913-588-6019

Principal Investigator

Reza Hejazi

PRINCIPAL INVESTIGATOR

University of Kansas

Frequently Asked Questions

Who can join the NCT07330284 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Pancreatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07330284 currently recruiting?

Yes, NCT07330284 is actively recruiting participants. Contact the research team at rhejazi@kumc.edu for enrollment information.

Where is the NCT07330284 trial being conducted?

This trial is being conducted at Kansas City, United States.

Who is sponsoring the NCT07330284 clinical trial?

NCT07330284 is sponsored by University of Kansas Medical Center. The principal investigator is Reza Hejazi at University of Kansas. The trial plans to enroll 950 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology